Brain Tumor News and Research

RSS

A Brain Tumor is the growth of abnormal cells in the tissues of the brain. Brain tumors can be benign (not cancer) or malignant (cancer).

LRIG1 could serve as important biomarker to distinguish between glioma types and grades

A new research paper was published in Oncotarget (Volume 16) on November 6, 2025, titled "LRIG1-3 in gliomas: LRIG1 protein expression decreased in higher grade gliomas."

12 Nov 2025

St. Jude study maps treatment strategy for rare infant gliomas

Clinician-scientists at St. Jude Children's Research Hospital and collaborators have conducted the largest study of infant-type hemispheric glioma (IHG) ever reported, uncovering key factors that could be used to guide treatment strategies for this rare pediatric brain tumor.

11 Nov 2025

Uppsala researchers develop Trojan horse approach for medulloblastoma treatment

The malignant pediatric brain tumor medulloblastoma is driven by proteins deep within the cancer cells, for which there are often no effective drugs available.

10 Nov 2025

Retrospective study highlights effective management of post-neurosurgery space-occupying cysts

Space-occupying cyst (SOC), a fluid-filled sac that grows in a confined area of the body, is one of the major complications associated with brain tumor resection. Understanding the clinical features and management principles for such cysts can help patients to experience a favorable prognosis.

7 Nov 2025

New analysis identifies safer treatment paths for children with medulloblastoma

By analyzing data from three clinical trials treating children with the brain tumor medulloblastoma, scientists at St. Jude Children's Research Hospital have designed an approach to safely reduce therapy, thereby lowering side effects.

5 Nov 2025

Fundamental challenges and cutting-edge strategies in developing new GBM CAR-T therapies

Glioblastoma (GBM), the most aggressive primary brain tumor, continues to portend a poor prognosis with median survival under two years, despite standard care involving surgery, radiation, and temozolomide chemotherapy.

30 Oct 2025

Study shows mRNA-based COVID vaccines enhance effectiveness of immune checkpoint therapy

Patients with cancer who received mRNA-based COVID vaccines within 100 days of starting immune checkpoint therapy were twice as likely to be alive three years after beginning treatment, according to a new study led by researchers at The University of Texas MD Anderson Cancer Center.

22 Oct 2025

New approach protects the brain from radiation-induced cognitive decline

While tremendous relief comes from successfully battling cancer, survivors can also experience cognitive impairments caused by the disease and its treatment.

14 Oct 2025

Innovative system accurately detects genetic mutations in the brain tumor within 25 minutes

A research team in Japan has developed an innovative system that can accurately detect genetic mutations in the brain tumor within just 25 minutes.

9 Oct 2025

Engineered virus therapy triggers powerful immune responses in glioblastoma

A new study led by Break Through Cancer's Accelerating Glioblastoma (GBM) Therapies Through Serial Biopsies TeamLab has revealed that an engineered virus therapy, CAN-3110, triggered powerful immune responses deep inside glioblastoma tumors that were invisible to standard imaging like MRI, according to early analyses of two patients with recurrent GBM.

9 Oct 2025

Repeated sampling offers insight into glioblastoma therapy response

A multi-institutional study from the Accelerating GBM Therapies Through Serial Biopsies TeamLab, led by investigators from the Mass General Brigham Cancer Institute, found that serially testing tumor samples can help detect when a cancer treatment is activating the immune system in recurrent glioblastoma (GBM), even when traditional imaging measures cannot.

8 Oct 2025

Nanomedicine emerges as a key tool to boost cancer immunotherapy

Scientists at the Fralin Biomedical Research Institute at VTC and their collaborators are exploring emerging trends in cancer immunotherapy, with back-to-back review articles published in Nature Cancer and Trends in Cancer that look at how nanotechnology could reprogram the immune system and help overcome tumors' defenses.

8 Oct 2025

AI tool accurately distinguishes between glioblastoma and primary central nervous system lymphoma

A Harvard Medical School–led research team has developed an AI tool that can reliably tell apart two look-alike cancers found in the brain but with different origins, behaviors, and treatments.

29 Sep 2025

New diagnostic methods and treatments needed to fight against Alzheimer's disease

The diagnosis and medical treatment of Alzheimer's disease, a condition that according to leading researchers in the field should be treated, has now advanced significantly.

24 Sep 2025

New study uncovers why dispersed glioblastoma cells are more dangerous

A new study, led by researchers at Sylvester Comprehensive Cancer Center part of the University of Miami Miller School of Medicine, captured details of glioblastoma that had never before been seen and revealed a surprise finding: Glioblastoma cells that "cluster" together with other cells of the same type are less deadly than those that disperse from these clusters.

18 Sep 2025

Abnormal protein activity found to promote cell migration and spread of glioblastoma

Ever wondered how the different cells in our body communicate with each other to fulfill their different roles-be it cells repairing a tissue injury or immune cells moving towards an invading pathogen (microorganisms that causes disease) to engulf it?

11 Sep 2025

New tool can predict where deadly brain cancer might reappear

Glioblastoma is a devastatingly effective brain cancer. Doctors can cut it out or blast it with radiation, but that only buys time. The cancer has an insidious ability to hide enough tumor cells in tissue around the tumor to allow it to return as deadly as ever.

9 Sep 2025

Targeting ADAR1 offers new hope against glioblastoma

The most common and aggressive type of adult brain cancer, glioblastoma multiforme (GBM) is notoriously resistant to treatment, with a median survival of just 14 months following diagnosis.

5 Sep 2025

Glutamate receptors found to drive pediatric brain tumor development

The most common type of brain tumor in children, pilocytic astrocytoma (PA), accounts for about 15% of all pediatric brain tumors.

1 Sep 2025

Multi-analyte test accurately identifies brain cancers using cerebrospinal fluid

A novel, multi-analyte test developed by researchers at the Johns Hopkins Kimmel Cancer Center, its Ludwig Center and the Johns Hopkins Department of Neurosurgery can accurately identify brain cancers using small samples of cerebrospinal fluid (CSF), offering a promising new tool to guide clinical decision-making.

27 Aug 2025